« previous next »
Pages: [1]

Author Topic: (AAN) PML risk cut by extending Tysabri dosing interval  (Read 237 times)

0 Members and 1 Guest are viewing this topic.

Offline agate

  • Administrator
  • *****
  • Posts: 9842
  • MS diagnosed 1980
  • Location: Pacific Northwest
Biogen starts Phase 3b trial to evaluate Tysabri extended dosing interval
« on: January 08, 2019, 03:34:20 pm »
From Medical News Today, January 7, 2019--"Biogen starts Phase 3B trial to evaluate Tysabri extended interval dosing for RRMS patients." The dosing regimen being studied would involve receiving Tysabri every 6 weeks instead of every 4 weeks.


https://multiplesclerosisnewstoday.com/2019/01/07/phase-3b-trial-tysabri-extended-interval-dosing-rrms/
« Last Edit: January 08, 2019, 03:37:39 pm by agate »
Report to moderator   Logged
MS Speaks--online for 17 years

SPMS, diagnosed 1980. Avonex 2001-2004. Copaxone 2007-2010. Glatopa (glatiramer acetate 40mg 3 times/week) since 12/16/20 - 3/16/24.
Pages: [1]
« previous next »
 

Related Topics

  Subject / Started by Replies Last post
0 Replies
155 Views 		Last post September 28, 2016, 04:53:58 pm
by agate
0 Replies
462 Views 		Last post May 16, 2017, 11:53:39 am
by agate
0 Replies
117 Views 		Last post June 11, 2017, 04:49:10 pm
by agate
0 Replies
167 Views 		Last post October 11, 2017, 10:47:48 am
by agate
0 Replies
29 Views 		Last post December 15, 2021, 09:25:42 pm
by agate